indazoles has been researched along with Bone Marrow Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, K; Ishida, H; Kanamitsu, K; Shimada, A; Tsukahara, H; Washio, K | 1 |
| Bourredjem, A; Daudigeos-Dubus, E; Farace, F; Geoerger, B; Monnet, Y; Opolon, P; Rössler, J; Vassal, G | 1 |
2 other study(ies) available for indazoles and Bone Marrow Neoplasms
| Article | Year |
|---|---|
A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy.
Topics: Adolescent; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Neoplasms; Fluorodeoxyglucose F18; Forkhead Box Protein O1; Humans; Indazoles; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Pancreatic Neoplasms; PAX3 Transcription Factor; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Microenvironment; Zoledronic Acid | 2020 |
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Topics: Animals; Apoptosis; Axitinib; Blotting, Western; Bone Marrow Neoplasms; Child; Drug Synergism; Endothelium, Vascular; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Sirolimus; Stem Cells; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2011 |